Analysis Of Market Landscape And Competitive Dynamics Of Major Manufacturers
Apr 26, 2026
Analysis of Market Landscape and Competitive Dynamics of Major Manufacturers
As a pivotal instrument in interventional radiology and diagnostic imaging, the Chiba needle market in 2025 exhibits a distinct landscape characterized by "domination by international brands and pursuit by local enterprises." According to surveys by YH Research (Honest Insight), the global Chiba biopsy needle market was valued at approximately RMB 2.02 billion in 2024 and is projected to maintain steady growth, reaching about RMB 3.04 billion by 2031, with a Compound Annual Growth Rate (CAGR) of 5.9%. Separate data indicates the market reached 1.2billion∗∗in2025andisexpectedtohit∗∗2.3 billion by 2033, growing at a CAGR of 8.2% from 2026 to 2033. The Chinese market stands out prominently; its Chiba biopsy needle market is estimated to reach RMB 5 billion in 2025, representing a 40% growth compared to 2020.
Global Competitive Landscape: Dominated by International Giants
The global competitive landscape is primarily dominated by international medical giants. Companies such as Cook Medical, Mermaid Medical, Blueneem Medical Devices, BD (Becton, Dickinson and Company), Doctor Japan, GEOTEK MEDICAL, PAJUNK, MEDITECH DEVICES, TSK Laboratory International, Volkmann MedizinTechnik, and Ace Medical Devices constitute the main industry participants. Additionally, multinationals like Boston Scientific, Smiths Medical, Terumo, and Medtronic hold significant positions in the Chiba needle market. These enterprises possess distinct advantages in the high-end segment due to their robust R&D capabilities, comprehensive product portfolios, and mature global sales networks.
China Market: Accelerating Import Substitution
In the Chinese market, the process of import substitution is accelerating. Current major brands include imports like Bard and Cook, alongside domestic players such as Suzhou-based medical device companies and Shanghai-based medical tech firms. With increasing national policy support for domestic medical devices, the market share of domestic Chiba needles has been rising annually, currently standing at around 40%. It is projected that by 2028, the domestic market share will exceed 60%, with breakthroughs occurring even in certain high-end product segments.
Product Segmentation and Applications
In terms of product structure, Chiba needles are finely segmented into various specifications. According to MedicalExpo data, diameter specifications range across 20G, 22G, 21G, 12G, 18G, 23G, 27G, 25G, 13G, 15G, 11G, 17G, 19G, 26G, 14G, 16G, and 24G, with lengths spanning from 30mm to 400mm. Disposable aspiration biopsy needles (Chiba) are utilized to obtain soft tissue biopsies under B-mode ultrasound or X-ray monitoring, targeting organs such as the liver, kidneys, prostate, spleen, lymph nodes, and various soft tissue tumors.
Regarding application distribution, downstream usage covers multiple scenarios like hospitals and clinics. According to YaoPinTong (Drug News) data, Chiba biopsy needles are used for aspirating tissue and cells, suitable for biopsies of the breast, kidneys, liver, lungs, thyroid, lymph nodes, and other soft tissue masses. Under ultrasound guidance, Chiba needles are employed in thyroid and lung biopsies, drainage procedures, and regional anesthesia (nerve blocks).
Regional Distribution and Policy Impact
Regional market distribution reveals significant geographical disparities globally. North America, Europe, and the Asia-Pacific (APAC) region represent the primary markets. North America was valued at $0.25 billion in 2024. By 2035, the APAC region is expected to capture the largest global market share. As the world's largest emerging market, China not only demonstrates rapid market expansion but also continuously enhances its technological innovation capabilities.
Price competition has intensified with the implementation of Volume-Based Procurement (VBP) policies. Although the competitive landscape in China's Chiba needle market remains somewhat fragmented, a trend of accelerated localization is evident. Supported by the "14th Five-Year Plan," which prioritizes high-end puncture devices, domestic enterprises are expanding their market share through technological upgrades and scaled production.
Technological Frontiers and Future Outlook
Technological innovation has become a critical dimension of manufacturer competition. A research team led by Professor Takashige Omatsu at Chiba University successfully fabricated the world's thinnest metal needle, featuring a tip diameter of approximately 50 nanometers (about 1/20,000th of a millimeter) and a length of 0.01mm. Made from the rare metal Tantalum, this needle could serve as a painless injector tip, holding promise for molecular-level micromachines and components in engineering and medical fields.
Future market competition will emphasize industrial chain integration and ecosystem building. Multinational corporations control the entire value chain from raw materials to finished products through vertical integration, while domestic firms establish collaborative innovation systems involving industries, universities, and research institutes through horizontal cooperation. As technological innovation accelerates, industry standards improve, and market competition intensifies, enterprises possessing core technologies, scaled production capacity, and sound cost control will prevail in the industry consolidation.
